83-43-2

• 常用中文名：甲基泼尼松龙
• 常用英文名：Methylprednisolone
• CAS号：83-43-2
• 分子式：C₂₂H₃₀O₅
• 分子量：374.471
• 相关类别： 原料药 激素及调节内分泌功能类药 肾上腺皮质激素类药
• 发布时间：2018-02-08 08:00:00
• 更新时间：2026-06-30 23:35:22
• Methylprednisolone是皮质类固醇,可作用于糖皮质激素受体。

名称

• 中文名: 6α-甲基泼尼松龙
• 英文名: 6α-methylprednisolone
• 中文别名: 甲基强的松龙/C1A; 甲基泼尼松龙/甲基强的松龙; 甲泼尼龙对照品; 甲基氢化泼尼松/甲泼尼龙/甲强龙/6Α-甲基强的松龙/六甲基泼尼松龙/皮质酮/皮质甾酮/甲基泼尼松龙/11Β,17Α,21-三羟基-6Α-甲基-1,4-孕甾二烯-3,20-二酮 6Α-甲基-11Β,17Α,21-三羟基-1,4-孕甾二烯-3,20-二酮; 甲基波尼松龙; 甲基泼尼松龙(甲强龙); 甲基强的松龙杂质; 甲基强的松龙琥珀酸氢盐杂质A; 琥珀酸甲泼尼龙杂质A; 甲基泼尼松龙溶液,100PPM; 甲泼尼龙; 甲基泼尼松龙-[D7]/精确称量; 甲基泼尼松龙标准溶液; 甲强龙; 皮质酮(肾上腺酮) 标准品; 甲醇中甲基泼尼松龙; 六甲基泼尼松龙; 6-Α-甲基泼尼松龙D4; 6Α-甲基强的松; 6Α-甲基-11Β,17Α,21-三羟基-1,4-孕甾二烯-3,20-二酮; Methylprednisolone (NSC-19987) 甲泼尼龙，S1733; 甲泼尼龙 标准品; 甲基泼尼松龙(甲基强的松龙)检测标准品; 甲醇中甲基泼尼松龙溶液标准物质; 11Β,17Α,21-三羟基-6Α-甲基-1,4-孕甾二烯-3,20-二酮; 11Β,17Α,21-三羟基-6Α-甲基-1,4-孕甾二烯-3,20-二酮6Α-甲基-11Β,17Α,21-三羟基-1,4-孕甾二烯-3,20-二酮6Α-甲基泼尼松龙甲基强的松龙甲基泼尼松龙; 甲基强的松龙 (甲泼尼龙); 甲泼尼龙杂质A; 氘7-甲基强的松; 甲基泼尼松龙标准溶液,100PPM; 11β,17α,21-三羟基-6α-甲基-1,4-孕甾二烯-3,20-二酮; 甲基强的松龙; 醋酸甲基强的松龙杂质B; 6α-甲基-11β,17α,21-三羟基-1,4-孕甾二烯-3,20-二酮; 皮質[甾]酮; 甲泼尼龙系统适用性 标准品; 六甲强龙(甲泼尼龙/甲基泼尼松龙/6-Α-METHYLPREDNISOLONE) 标准品; Methylprednisolone (NSC-19987) 甲泼尼龙,S1733; 甲基氢化泼尼松/甲基泼尼松龙; 甲基强的松龙(醋酸甲基强的松龙杂质B,琥珀酸氢甲基强的松龙杂质A); 甲泼尼龙(甲基泼尼松龙); 甲基泼尼松龙(标准品); *甲基泼尼松龙系列(甲强龙); 甲基泼尼松龙/甲基泼尼松龙醋酸酯杂质B/甲基泼尼松龙琥珀酸钠杂质AMETHYLPREDNISOLONE; 甲基泼尼松(醋酸甲基泼尼龙杂质B,琥珀酸氢甲基泼尼松龙杂质A); 甲基强的松龙标准品; 甲基泼尼松龙/甲基氢化泼尼松; Methylprednisolone 1000mg试剂; 甲基氢化泼尼松; 6α-甲基强的松龙; 醋酸甲泼尼龙杂质B
• 英文别名: MEDRONE; 6α-Methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione; 20-dione,6-alpha-methyl-11-beta-17,21-trihydroxy-pregna-4-diene-3; 6α-Methylprednisolone,11β,17α,21-Trihydroxy-6α-methyl-1,4-pregnadiene-3,20-dione, 6α-Methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione, Medrol, Medrone; EINECS 201-476-4; Methylprednisolone Impurity A; 11,17,21-trihydroxy-6-methyl-1,4-pregnadiene-3,20-dione; 6alpha-methylprednisolone; Methyl Prednisolone Hydrogen succinate Impurity A; (6S,8S,9S,10R,11S,13S,14S,17R)-17-glycoloyl-11,17-dihydroxy-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; Suprametil; 1,4-PREGNADIEN-6-ALPHA-METHYL-11-BETA, 17,21-TRIOL-3,20-DIONE; 1,4-Pregnadien-6a-Methyl-11,17a,21-triol-3,20-dione-d2; (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-triMethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; Besonia; 6ALPHA-METHYL-11BETA,17ALPHA,21-TRIHYDROXY-1,4-PREGNADIENE-3,20-DIONE; 6-ALPHA-METHYLPREDNISOLONE; delta(sup1)-6-alpha-methylhydrocortisone; (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyethanoyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; 11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione Medrol; 11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; 6-ALPHA-METHYL-11BETA, 17D,21-TRIHYDROXY-1,4-PREGNADIENE-3,20-DIONE; delta1-6alpha-Methylhydrocortisone; (6α,11β)-11,17,21-Trihydroxy-6-Methylpregna-1,4-diene-3,20-dione; 11BETA,17ALPHA,21-TRIHYDROXY-6ALPHA-METHYL-1,4-PREGNADIENE-3,20-DIONE; delta(1)-6alpha-methylhydrocortisone; 6-alpha-Methyl Prednisolone-d4; 11b,17a,21-trihydroxy-6a-methyl-1,4-pregnene-3,20-dione; METHYLPREDNISOLONE; 20-dione,11beta,17,21-trihydroxy-6alpha-methyl-pregna-4-diene-3; 1-dehydro-6alpha-methylhydrocortisone; MEDROL; 6-A-METHYLPREDNISOLONE; (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione; Methylprednisolone Hydrogen Succinate Impurity A; 20-dione,11-beta,17,21-trihydroxy-6-alpha-methyl-pregna-4-diene-3; Urbason; 11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione; Urbasone; 6A-METHYLPREDNISOLINE; Methylprednisolone-d4; Methylprednisolone Base & Acetate; a-methapred; MFCD00010591; Medrol, Medrone, 11β,17α,21-Trihydroxy-6α-methyl-1,4-pregnadiene-3,20-dione, 6α-Methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione; Methylprednisolone I0E1700.995mg/mg(dr); Do-Medrol; tisone-wyeth; 6alpha-methyl-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione; 6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione; Methylprednisolone Acetate Impurity B; Wyacort; METHYPEDNISOLINE; Testosterone THP Ether; 17-Dehydroxy 11-O-Trimethylsilyl 6α 6-ALFA-METHYLPREDNISOLONE; 20-dione,11,17,21-trihydroxy-6-methyl-,(6alpha,11beta)-pregna-4-diene-3

物化性质

• 密度: 1.3±0.1 g/cm3
• 沸点: 571.8±50.0 °C at 760 mmHg
• 熔点: 228-237°C (dec.)
• 分子式: C₂₂H₃₀O₅
• 分子量: 374.471
• 闪点: 313.7±26.6 °C
• 精确质量: 374.209320
• PSA: 94.83000
• LogP: 1.99
• 外观性状: 白色至灰白色结晶粉末
• 蒸汽压: 0.0±3.6 mmHg at 25°C
• 折射率: 1.603
• 储存条件:

  本品应密封干燥保存。

• 水溶解性: chloroform/methanol (9:1): 50 mg/mL, clear, faintly yellow
• 分子结构:

  1、 摩尔折射率：100.08

  2、 摩尔体积（m³/mol）：291.4

  3、 等张比容（90.2K）：804.8

  4、 表面张力（dyne/cm）：58.1

  5、 极化率（10^-24cm³）：39.67

• 计算化学:

  1.疏水参数计算参考值（XlogP）:无

  2.氢键供体数量:3

  3.氢键受体数量:5

  4.可旋转化学键数量:2

  5.互变异构体数量:9

  6.拓扑分子极性表面积94.8

  7.重原子数量:27

  8.表面电荷:0

  9.复杂度:754

  10.同位素原子数量:0

  11.确定原子立构中心数量:8

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:0

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:1

• 更多:

  1. 性状：无色结晶。

  2. 密度（g/mL,25/4℃）：不确定

  3. 相对蒸汽密度（g/mL,空气=1）：不确定

  4. 熔点（ºC）：228～237℃

  5. 沸点（ºC,常压）：不确定

  6. 沸点（ºC,5.2kPa）：不确定

  7. 折射率：不确定

  8. 闪点（ºC）：不确定

  9. 比旋光度（º）：[α]_D²⁰ +83°（二氧六环中）。

  10. 自燃点或引燃温度（ºC）：不确定

  11. 蒸气压（kPa,25ºC）：不确定

  12. 饱和蒸气压（kPa,60ºC）：不确定

  13. 燃烧热（KJ/mol）：不确定

  14. 临界温度（ºC）：不确定

  15. 临界压力（KPa）：不确定

  16. 油水（辛醇/水）分配系数的对数值：不确定

  17. 爆炸上限（%,V/V）：不确定

  18. 爆炸下限（%,V/V）：不确定

  19. 溶解性：略微溶于乙醇、二氧六环、甲醇，微溶于丙酮、氯仿，极微溶于乙醚，不溶于水

生物活性

• 描述: Methylprednisolone是皮质类固醇,可作用于糖皮质激素受体。
• 相关类别:
  信号通路 >> 自噬 >> 自噬
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 糖皮质激素受体
  研究领域 >> 炎症/免疫
• 参考文献:

  [1]. Strupp, M., et al., Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med, 2004. 351(4): p. 354-61.

  [2]. Bracken, M.B., et al., A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med, 1990. 322(20): p. 1405-11.

MSDS

Name: 6-alpha-Methylprednisolone 99% Material Safety Data Sheet Synonym: Medro CAS: 83-43-2 Section 1 - Chemical Product MSDS Name:6-alpha-Methylprednisolone 99% Material Safety Data Sheet Synonym:Medro Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS CAS# Chemical Name content EINECS# 83-43-2 6-alpha-Methylprednisolone 99% 201-476-4 Hazard Symbols: XN Risk Phrases: 40 Section 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Limited evidence of a carcinogenic effect. Potential Health Effects Eye: May cause eye irritation. Skin: Harmful if absorbed through the skin. Ingestion: Harmful if swallowed. Inhalation: Harmful if inhaled. May cause irritation of the respiratory tract with burning pain in the nose and throat, coughing, wheezing, shortness of breath and pulmonary edema. Chronic: Not available. Section 4 - FIRST AID MEASURES Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid. Skin: Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Ingestion: Get medical aid. Wash mouth out with water. Inhalation: Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Notes to Physician: Section 5 - FIRE FIGHTING MEASURES General Information: As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Extinguishing Media: Use foam, dry chemical, or carbon dioxide. Section 6 - ACCIDENTAL RELEASE MEASURES General Information: Use proper personal protective equipment as indicated in Section 8. Spills/Leaks: Vacuum or sweep up material and place into a suitable disposal container. Section 7 - HANDLING and STORAGE Handling: Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes. Storage: Store in a cool, dry place. Store in a tightly closed container. Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION Engineering Controls: Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 83-43-2: Personal Protective Equipment Eyes: Not available. Skin: Wear appropriate protective gloves to prevent skin exposure. Clothing: Wear appropriate protective clothing to prevent skin exposure. Respirators: Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced. Section 9 - PHYSICAL AND CHEMICAL PROPERTIES Physical State: Powder Color: white Odor: Not available. pH: Not available. Vapor Pressure: Not available. Viscosity: Not available. Boiling Point: Not available. Freezing/Melting Point: 227-231 deg C Autoignition Temperature: Not available. Flash Point: Not available. Explosion Limits, lower: Not available. Explosion Limits, upper: Not available. Decomposition Temperature: Solubility in water: Insoluble. Specific Gravity/Density: Molecular Formula: C22H30O5 Molecular Weight: 374.207 Section 10 - STABILITY AND REACTIVITY Chemical Stability: Stable. Conditions to Avoid: Incompatible materials. Incompatibilities with Other Materials: Strong oxidizing agents, acids, acid chlorides, carbon dioxide, acid anhydrides. Hazardous Decomposition Products: Nitrogen oxides, carbon monoxide, carbon dioxide. Hazardous Polymerization: Will not occur. Section 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 83-43-2: TU4146000 LD50/LC50: CAS# 83-43-2: Oral, rat: LD50 = >4 gm/kg. Carcinogenicity: 6-alpha-Methylprednisolone - Not listed by ACGIH, IARC, or NTP. Other: See actual entry in RTECS for complete information. Section 12 - ECOLOGICAL INFORMATION Section 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations. Section 14 - TRANSPORT INFORMATION IATA No information available. IMO No information available. RID/ADR No information available. Section 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives Hazard Symbols: XN Risk Phrases: R 40 Limited evidence of a carcinogenic effect. Safety Phrases: S 36/37 Wear suitable protective clothing and gloves. S 45 In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). WGK (Water Danger/Protection) CAS# 83-43-2: No information available. Canada CAS# 83-43-2 is listed on Canada's NDSL List. CAS# 83-43-2 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 83-43-2 is listed on the TSCA inventory. SECTION 16 - ADDITIONAL INFORMATION N/A

毒性和生态

毒理学数据: 1、急性毒性： 人肠道TDLO：2400 ug/kg；人静脉TDLO：60 mg/kg/3D-I 人静脉TDLO：20 mg/kg/45W-C 大鼠口径LD50：>4mg/kg； 小鼠腹腔LD50：2292mg/kg； 2、其他多剂量毒性： 狗口径TDL0：210 mg/kg/6W-I CHEMICAL IDENTIFICATION RTECS NUMBER : TU4146000 CHEMICAL NAME : Pregna-1,4-diene-3,20-dione, 6-alpha-methyl-11-beta-17,21-trihydroxy- CAS REGISTRY NUMBER : 83-43-2 BEILSTEIN REFERENCE NO. : 2340300 LAST UPDATED : 199701 DATA ITEMS CITED : 9 MOLECULAR FORMULA : C22-H30-O5 MOLECULAR WEIGHT : 374.52 WISWESSER LINE NOTATION : L E5 B666 OV AHTTT&J A1 CQ E1 FV1Q FQ L1 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral SPECIES OBSERVED : Human - woman DOSE/DURATION : 2400 ug/kg TOXIC EFFECTS : Cardiac - change in rate Lungs, Thorax, or Respiration - respiratory depression Nutritional and Gross Metabolic - body temperature increase REFERENCE : BJANAD British Journal of Anesthesia. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1923- Volume(issue)/page/year: 69,422,1992 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Human - woman DOSE/DURATION : 60 mg/kg/3D-I TOXIC EFFECTS : Cardiac - pulse rate increase, without fall in BP Vascular - BP lowering not characterized in autonomic section Nutritional and Gross Metabolic - body temperature increase REFERENCE : AIMEAS Annals of Internal Medicine. (American College of Physicians, 4200 Pine St., Philadelphia, PA 19104) V.1- 1927- Volume(issue)/page/year: 99,282,1983 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Human - woman DOSE/DURATION : 20 mg/kg/45M-C TOXIC EFFECTS : Cardiac - arrhythmias (including changes in conduction) REFERENCE : JRHUA9 Journal of Rheumatology. (920 Yonge St., Suite 608, Toronto, Ont., Canada) V.1- 1974- Volume(issue)/page/year: 13,477,1986 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >4 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,832,1982 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 2292 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,832,1982 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 210 mg/kg/6W-I TOXIC EFFECTS : Kidney, Ureter, Bladder - other changes in urine composition Nutritional and Gross Metabolic - weight loss or decreased weight gain Nutritional and Gross Metabolic - changes in sodium REFERENCE : TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 1,305,1959 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 84067 No. of Facilities: 33 (estimated) No. of Industries: 2 No. of Occupations: 1 No. of Employees: 272 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 84067 No. of Facilities: 42 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 2047 (estimated) No. of Female Employees: 983 (estimated)

安全

• 个人防护装备: Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
• 危害码 (欧洲): Xi
• 风险声明 (欧洲): R36/37/38
• 安全声明 (欧洲): S22-S36
• 危险品运输编码: NONH for all modes of transport
• WGK德国: 2
• RTECS号: TU4146000

合成路线